Navigation Links
MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results
Date:5/3/2011

fiscal 2011 full year operating expenses, excluding non-cash charges such as stock-based compensation and depreciation, to be approximately $50 to $55 million. In addition, the Company currently anticipates capital expenditures in 2011 to be approximately $4 to $5 million. As previously disclosed, the Company anticipates loan payments of approximately $8 million in 2011 related to a working capital loan. Collaboration revenues are estimated to be approximately $65 million in 2011. This estimate includes amortization of the upfront payment received in February 2011 and a milestone payment that the Company would be eligible to receive in 2011 under its collaboration agreement with Allergan, if a certain milestone is met.

About MAP PharmaceuticalsMAP Pharmaceuticals is an emerging biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX, an orally inhaled investigational drug for the acute treatment of migraine. The Company has reported positive results from its Phase 3 trial of LEVADEX and has entered into a collaboration agreement with Allergan, Inc. to co-promote LEVADEX to neurologists and pain specialists in the U.S. MAP Pharmaceuticals also applies its proprietary drug particle and inhalation technologies to generate new pipeline opportunities by enhancing the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

Forward-Looking StatementsIn addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals' LEVADEX product candidate and MAP Pharmaceuticals' expected cash requirements during 2011 describe
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
3. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
4. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
10. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
11. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DTS Language Services, Inc . is pleased ... Life Science organizations who need document translations. Clients will ... their documents in advance with a selection of nearly 50 ... often a critical factor in clinical and scientific fields, and ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... throughput research solutions, today announced that Lupin Limited, one ... of Freeslate’s CM Protégé PharmD System for ... in Mumbai, India, is focused on a wide range ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, ... exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, ... the Russian Federation , ... Independent States (CIS). Nemonoxacin is a novel antibiotic for the ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Carahsoft and ... Thursday, January 23, 2014 at 2pm EST (11am PST), ... The topic focuses on how technology can turn raw, ... decisions for government agencies. The online webinar will last ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2
... the rising trend toward miniaturization, carbon nanotubes which ... and possess several unique and very useful properties ... blocks in nanosized electronic and mechanical devices. But it ... tendency to clump together, that make it difficult for ...
... testament to tight integration and ... excellent ... ), a,leader in radiology and medical image and information management solutions,today ... than 100 facilities that use MEDITECH(TM) as their health,information system. AMICAS ...
... device industry to benefit ... trial recruitment efforts, MINNEAPOLIS, May 27 ... has strengthened the,pharmaceutical side of its business with ... a commitment to leveraging differentiators unique,to the medical ...
Cached Biology Technology:Weizmann Institute scientists create new nanotube structures 2AMICAS Announces Integrations at More Than 100 MEDITECH Facilities 2AMICAS Announces Integrations at More Than 100 MEDITECH Facilities 3ThreeWire Expands Presence in the Pharmaceutical Arena 2
(Date:4/24/2014)... --- New research shows that cells are more resilient ... thought. Even when missing critical components, cells can adapt ... way. , In a study published in this week,s ... Michigan State University showed that cells can grow normally ... , "Our genetic information is stored in DNA, which ...
(Date:4/24/2014)... is very pleased to announce that it has assumed ... from the University of Wisconsin. , The ... open-access, peer-reviewed journal that publishes papers on all aspects ... from the molecular to the ecological -- as well ... available to individuals and institutions, and it provides a ...
(Date:4/24/2014)... be improved with new insights into the make-up of ... the Amazon Basin have revealed unprecedented detail of the ... by comparing satellite maps with hundreds of field plots. ... more accurately the amount of carbon each tree can ... schemes, in which trees are given a cash value ...
Breaking Biology News(10 mins):Cell resiliency surprises scientists 2ESA to publish the Journal of Insect Science 2Amazon rainforest survey could improve carbon offset schemes 2
... National Institute of General Medical Sciences, part of the ... Models of Infectious Disease Agent Study for a research ... led by Stephen Eubank, professor. Infectious diseases pose ... worldwide. The Models of Infectious Disease Agent Study (MIDAS) ...
... There might be a time when instead of just drinking ... skin as a way of preventing harmful sun damage or ... caffeine guards against certain skin cancers at the molecular level ... ATR. Scientists believe that based on what they have learned ...
... from NYU Langone Medical Center,s Departments of Orthopaedic Surgery ... used to detect subtle changes in joint cartilage microstructure ... key markers of early osteoarthritis (OA). By using these ... can shift the management of the disease from eventual ...
Cached Biology News:National Institutes of Health renews successful infectious disease research study 2National Institutes of Health renews successful infectious disease research study 3More evidence that caffeine lowers risk of skin cancer 2NYU Langone experts find MRI techniques can detect early osteoarthritis 2
Human Cystatin F MAb (Clone 292103)...
Rat CNTF R alpha Affinity Purified Polyclonal Ab...
... Ac-DEVD-CHO is an inhibitor ... The concentration of inhibitor ... activity must be determined ... Ten micromolar inhibitor is ...
TUNEL Apoptosis Detection Kit...
Biology Products: